Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Stocks to watch out for today: Wipro, Britannia Industries, Cipla, Biocon, Gland Pharma, Kilpest India and more

Stocks in news: Wipro, Britannia Industries, Cipla, Biocon and more

BNP Paribas Arbitrage offloaded over 18,00,164 lakh shares at an average price of Rs 405 apiece of IT major Wipro for Rs 72.9 crore through an open market transaction.

Stocks in the news: Wipro, Britannia, Cipla, IDFC, Biocon and Gland Pharma

Stock Market News Live: Sensex and Nifty touched record highs in early deals today, extending their gains for the sixth straight session. Asian stocks rebounded as South Korea’s KOSPI moved 0.35 per cent higher, the Shanghai Composite index rose 1.63 per cent higher and Hong Kong’s Hang Seng Index j…

Share Market News Live: Sensex hits all-time high, Nifty tops 18,650; HUL, Nestle, Cipla among top gainers

Cipla rose 1.10% to Rs 1113.40 after the company announced the launch of Leuprolide Acetate Injection Depot 22.5mg, the approval for which was granted by the US FDA based on an NDA submitted under the 505(b)(2) regulatory pathway.

Cipla gains on launching US FDA-approved prostate cancer treatment drug

This is the second pharma merger and acquisition (M&A) transaction that has been called off or postponed recently due to market volatility and valuation mismatch. Hyderabad-based Aurobindo Pharma had also scrapped the demerger and sale of its injectables arm Eugia Pharma Specialities to Blackstone e…

Medley-Cipla deal talks called off over valuation issues

U.S. FDA designates Cipla’s Goa plant as ‘Official Action Indicated’

It states that an FDA inspection revealed significant objectionable conditions or practices and action must be taken to address the issues.

U.S. FDA Designates Cipla’s Goa Plant As ‘Official Action Indicated’

According to USFDA definition, OAI means “objectionable conditions were found and regulatory administrative sanctions by FDA are indicated” during inspections

USFDA designates Cipla’s Goa plant as ‘Official Action Indicated’

Speaking to ET NOW's Nikunj Dalmia from Cipla's R & D Centre, MD & Global CEO, Umag Vohra shares the importance of the R & D centre where over 1000 scientist work, as the place has produced multiple big products for the company. Moreover, speaking about India, he states that consumption in non-urban India is growing strong. Furthermore, while talking on a broader spectrum he said that India-based companies with high revenue coming from India are doing well, as there has been a shift in consumption patterns, where emerging markets are showing signs of high consumption. Find out more in this special interview, only on ET Now.

#cipla #ciplalimited #ciplastock
Subscribe To ET Now For Latest Updates On Stocks, Business News, Trading | https://bit.ly/SubscribeToETNow

To Stay Updated Download the Times Now App :-
Android Google Play :  https://goo.gl/zJhWjC
Apple App Store :  https://goo.gl/d7QBQZ

Social Media Links :-
Twitter - http://goo.gl/hA0vDt
Facebook - http://goo.gl/5Lr4mC
G+ - http://goo.gl/hYxrmj
Website - www.etnownews.com

Subscribe Now To Our Network Channels:-
Times Now: https://bit.ly/SubscribeToTimesNow
Mirror Now: https://bit.ly/SubscribeToMirrorNow

Pushed via Slike

Exclusive From Cipla's R & D Centre: MD & Global CEO Umag Vohra Speaks To ET NOW | Cipla Limited

The suit is expected to impact Natco Pharma, Dr Reddy’s Labs, Cipla, and Zydus Lifesciences. All these companies had launched Revlimid during the second COVID-19 wave in September 2021

Pharma stocks slip on concerns over first anti-competitive US lawsuit against ‘Revlimid’ makers

In an exclusive conversation with Nikunj Dalmia, Cipla's MD & Global CEO, Umang Vohra states that consumption in non-urban India is growing strong and that the demand and volume dynamics of India are very strong while the pecking order is very clear. He also added that it is a tough time for the product cycle and that the US is a highly consolidated market. To know more, watch the interview only on ET NOW
Subscribe To ET Now For Latest Updates On Stocks, Business News, Trading | https://bit.ly/SubscribeToETNow

To Stay Updated Download the Times Now App :-
Android Google Play :  https://goo.gl/zJhWjC
Apple App Store :  https://goo.gl/d7QBQZ

Social Media Links :-
Twitter - http://goo.gl/hA0vDt
Facebook - http://goo.gl/5Lr4mC
G+ - http://goo.gl/hYxrmj
Website - www.etnownews.com

Subscribe Now To Our Network Channels:-
Times Now: https://bit.ly/SubscribeToTimesNow
Mirror Now: https://bit.ly/SubscribeToMirrorNow

Pushed via Slike

Exclusive | "Indian Pharma Markets Are Now One Of The Main Growth Engines,": Umang Vohra, Cipla

Cipla Limited is an India-based company that is primarily engaged in the business of pharmaceuticals. The Company’s segments include Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The Company's geographical segments include India, the United States, South Africa and Rest of the World. The Company has its network of manufacturing, trading and other incidental operations in India and International markets. The Company has approximately 46 manufacturing sites.

Cipla Ltd

Cipla Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Stocks in news: Wipro, Britannia Industries, Cipla, Biocon and more

Stocks in the news: Wipro, Britannia, Cipla, IDFC, Biocon and Gland Pharma

Share Market News Live: Sensex hits all-time high, Nifty tops 18,650; HUL, Nestle, Cipla among top gainers

Cipla gains on launching US FDA-approved prostate cancer treatment drug

Medley-Cipla deal talks called off over valuation issues

U.S. FDA designates Cipla’s Goa plant as ‘Official Action Indicated’

U.S. FDA Designates Cipla’s Goa Plant As ‘Official Action Indicated’

USFDA designates Cipla’s Goa plant as ‘Official Action Indicated’

News Video

Exclusive From Cipla's R & D Centre: MD & Global CEO Umag Vohra Speaks To ET NOW | Cipla Limited

Pharma stocks slip on concerns over first anti-competitive US lawsuit against ‘Revlimid’ makers

Cipla Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Stocks in news: Wipro, Britannia Industries, Cipla, Biocon and more

Stocks in the news: Wipro, Britannia, Cipla, IDFC, Biocon and Gland Pharma

Share Market News Live: Sensex hits all-time high, Nifty tops 18,650; HUL, Nestle, Cipla among top gainers

Cipla gains on launching US FDA-approved prostate cancer treatment drug

Medley-Cipla deal talks called off over valuation issues

U.S. FDA designates Cipla’s Goa plant as ‘Official Action Indicated’

U.S. FDA Designates Cipla’s Goa Plant As ‘Official Action Indicated’

USFDA designates Cipla’s Goa plant as ‘Official Action Indicated’

News Video

Exclusive From Cipla's R & D Centre: MD & Global CEO Umag Vohra Speaks To ET NOW | Cipla Limited

Pharma stocks slip on concerns over first anti-competitive US lawsuit against ‘Revlimid’ makers

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock